(Updates to add stock movement in the headline and the last paragraph)
ResMed (ASX:RMD) logged $2.95 in non-GAAP EPS for the fiscal fourth quarter, compared with $2.55 a year ago, a Friday statement showed.
Analysts polled by FactSet expected earnings of $2.89.
For the three months ended June 30, revenue was $1.46 billion versus $1.35 billion previously, the Australia-listed global medical technology and digital health company added. Analysts surveyed by FactSet expected $1.46 billion.
The board declared a quarterly dividend of $0.66 per share, up 10% from the previous quarterly dividend, payable Sept. 24 to shareholders on record as of Aug. 20.
The company's shares fell past 5% in recent Friday trade.